Anginal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anginal

Property Description
Active Ingredient Isosorbide Mononitrate (ISMN)
Form Tablets, Sustained-release tablets, Extended-release capsules
Pharmacological Class Organic Nitrate, Vasodilator, Anti-anginal agent
General Purpose Long-term cardiovascular support and prevention (prophylaxis)
Origin Synthetic chemical compound

What is Anginal and its Pharmacological Type?

Anginal is a prescription-only medication primarily identified by its active ingredient, Isosorbide Mononitrate (ISMN). The drug is classified as an anti-anginal agent belonging to the organic nitrate pharmacological class and functions as a powerful vasodilator, acting on the vascular system to provide consistent long-term cardiovascular support. This single-ingredient product, a synthetic chemical compound, is clinically recognized for its reliable therapeutic profile. Unlike related dinitrate compounds, Isosorbide Mononitrate is already the biologically active molecule, a distinguishing characteristic that simplifies its action within the body.


Composition and Available Pharmaceutical Forms

The core composition of Anginal relies exclusively on Isosorbide Mononitrate as the sole active substance. The medication is administered via the oral route in several dosage forms, including conventional tablets and specialized preparations like sustained-release tablets and extended-release capsules. These forms are created by combining the active ingredient with solid pharmaceutical excipients. Pharmacological studies confirm that the design of the sustained and extended formulations ensures the gradual release of ISMN over an extended period, which helps maintain steady therapeutic levels necessary for continuous care.


The General Purpose of This Vasodilator

The general purpose of this medication is to reduce the workload placed upon the heart by consistently widening blood vessels throughout the body. The vasodilator effect of the organic nitrate is most pronounced in the veins, causing them to relax and accommodate a greater volume of blood. This mechanical effect effectively decreases the amount of blood returning to the heart, a key mechanism known as reducing the cardiac preload. By lowering the heart's effort and subsequent oxygen demand, Anginal helps maintain the long-term stability and prophylaxis necessary for managing conditions involving chronic chest discomfort.

Regulatory References

  1. Isosorbide - StatPearls - NCBI Bookshelf

What side effects are possible with Anginal?

Possible Side Effects and Safety Information

The officially documented safety profile for Anginal (Isosorbide Mononitrate) is strongly influenced by its primary action as a potent vasodilator, with adverse reactions categorized by frequency and the body system affected, according to regulatory standards.

Frequency-Classified Adverse Reactions

The most frequent reaction is classified as Very Common (ge 1/10), which is a throbbing headache. Side effects classified as Common (1-10%) include dizziness, tachycardia (increased heart rate), orthostatic hypotension (low blood pressure upon standing), and asthenia (weakness).

Reactions classified as Uncommon (0.1-1%) include nausea, vomiting, flushing, and allergic skin reactions. Uncommon adverse effects related to severe drops in blood pressure include aggravated angina pectoris and circulatory collapse.

System-Organ Classes and Safety Constraints

Adverse events are primarily observed in the Nervous System (e.g., headache, dizziness) and Vascular Disorders (e.g., hypotension). Serious adverse reactions officially documented include severe hypotension and syncope (fainting).

Safety notes specify that the Very Common headache is typically most pronounced at the start of therapy but often diminishes or resolves after the first 1–3 weeks of continuous use. Furthermore, older adults may have a greater risk for orthostatic hypotension. The medicine is absolutely contraindicated for use with Phosphodiesterase type-5 (PDE5) inhibitors due to the risk of life-threatening severe hypotension.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Isosorbide Mononitrate (Anginal) primarily manifests through symptoms related to profound vasodilatation and hemodynamic instability, as documented in official regulatory sources. Individuals who suspect an overdose must seek emergency medical attention immediately.

Documented Overdose Manifestations

Overdose presentations include a prompt fall in blood pressure (hypotension), which can be severe, along with neurological effects such as a persistent and throbbing headache, confusion, vertigo, and visual disturbances. Severe outcomes include circulatory collapse, seizure, and progression to coma. A rare but severe complication associated with nitrate toxicity is methemoglobinemia.

Emergency Actions and Management

Regulators mandate that emergency services (such as 911) must be contacted immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Management is symptomatic and supportive. Treatment typically involves interventions directed toward increasing central fluid volume, such as the administration of normal saline and elevation of the extremities. The use of powerful vasoconstrictors is generally not recommended in this setting. Methylene Blue is the documented antidote for severe methemoglobinemia. Special caution, including invasive monitoring, may be required for patients with renal disease or congestive heart failure due to the risks of fluid administration.

Therapeutic Uses of Anginal

Anginal (Isosorbide Mononitrate) may be part of symptomatic management for cardiovascular conditions, focusing on long-term prophylaxis. This medication is commonly used to help with the prophylaxis of angina pectoris (chest pain) in individuals with coronary artery disease. This therapy is considered relevant in conditions involving recurrent or episodic manifestations of chest discomfort.

Symptom Relief and Prophylaxis

This medication is applied in clinical settings that involve symptoms that interfere with daily functioning, such as chest pressure and pain patterns triggered by exertion. The core therapeutic benefit is to provide support that helps ease the overall symptom burden and may assist with supporting the management of the frequency and severity of anginal attacks.

The main indications where this is used include the prophylaxis of stable angina and as an adjunctive treatment for heart failure. In these contexts, Anginal supports the patient during difficult episodes and may assist with maintaining a sense of stability when symptoms are more noticeable.


Quick Fact

Quick Fact: Relief for Recurrent Chest Discomfort

  • Type of use: Long-term management (prophylaxis).
  • Focus: Supporting the management of the frequency and severity of episodes.
  • Context: Used when symptoms are triggered by exertion or stress.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Anginal? (Isosorbide Mononitrate)

Anginal is intended for use by adult patients for the prophylaxis of angina pectoris. Its eligibility is strictly defined by regulatory documents based on a patient's concurrent status and other health conditions.

The medicine is contraindicated and must not be used by patients with known hypersensitivity to nitrates, or those who are taking Phosphodiesterase type-5 (PDE-5) inhibitors (like sildenafil) or the sGC stimulator riociguat. Use is also prohibited in patients experiencing acute circulatory failure, cardiogenic shock, or severe hypotension (blood pressure le 90 mm Hg systolic).

Use is restricted or requires caution in several populations. Official guidance states that caution should be exercised in patients with severe renal or hepatic impairment, hypothyroidism, or a recent history of myocardial infarction. For children, the safety and efficacy have not been established. Use during pregnancy or lactation is permitted only if the regulatory assessment determines the possible benefits outweigh the potential hazards or risks.

What should I know about interactions with other medicines?

Interaction Scope

Category Details
Medicinal product categories with documented interactions: Phosphodiesterase type-5 (PDE5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Other Vasodilators, Antihypertensive Agents, Ergot Alkaloids.
Specific interacting medicines (if explicitly listed): Sildenafil, Tadalafil, Vardenafil, Riociguat, Dihydroergotamine.
Mechanistic basis of interactions (only if stated in label): Additive Vasodilating Effects; Altered Exposure (increased blood levels of Dihydroergotamine).
Timing-based interaction rules (if applicable): Mandatory waiting period (e.g., 48 hours after last Tadalafil dose) required before nitrate administration.
Population-specific interaction notes (if applicable): None formally documented where an interaction's severity is stated in the label to be modified by a patient population.
Interaction-related restrictions: Contraindicated combinations are strictly prohibited due to the risk of severe hypotension.

Interaction Classifications (High-Level)

Classification Details
Interaction severity classification (as defined in official documents): Contraindicated Combinations (PDE5 inhibitors, sGC stimulators); Clinically Significant Pharmacodynamic Reinforcement (other antihypertensives); Exposure-Altering Interaction (Ergot Alkaloids).
Regulatory basis (EMA / FDA / etc.): Official national prescribing information (e.g., FDA DailyMed, EMA SmPC).
Interaction-context constraints (as defined in official documents): Additive vasodilatory effects extend to Alcohol (Ethanol), which may increase the incidence of hypotension-related symptoms. Food is documented as not affecting absorption.

Resulting Interaction Structure

Official Interaction Statements:

  • Co-administration with PDE5 Inhibitors (e.g., Sildenafil) is contraindicated due to the potential for severe hypotension and syncope.
  • The use of Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) is also contraindicated due to the formally stated risk of additive systemic hypotension.
  • The effects are additive with other antihypertensive agents and vasodilators, leading to a documented risk of marked symptomatic orthostatic hypotension.
  • Co-administration may increase the blood level of specific Ergot Alkaloids (e.g., Dihydroergotamine), which can amplify the hypertensive effects of the co-administered drug.

Connection to the overall interaction profile (4 sentences):

Regulatory documents define the product's interaction structure primarily through two domains: contraindicated combinations due to severe blood pressure drops, and pharmacodynamic potentiation that necessitates caution with other hypotensive agents. The most significant constraint is the absolute prohibition of co-administration with PDE5 inhibitors and sGC stimulators. The official profile also includes a specific exposure-altering restriction, noting that the drug can increase the plasma concentration of certain Ergot Alkaloids. Alcohol is identified as an additive substance, while food is formally noted as being absent from the interaction profile.

Mechanism of Action

️ Molecular Mechanism of Isosorbide Mononitrate

The action of Isosorbide Mononitrate (ISMN) begins inside the vascular smooth muscle cells, where it is biologically converted by an enzyme, primarily Mitochondrial Aldehyde Dehydrogenase (mtALDH). This conversion is critical as it releases the signaling molecule, Nitric Oxide (NO), which acts as the primary mediator of the drug's effect. This initial step of enzymatic bioactivation is essential, as the subsequent physiological effects depend upon Nitric Oxide generation at the site of action.

Once released, Nitric Oxide activates the enzyme soluble Guanylate Cyclase (sGC), triggering a rapid increase in the cellular messenger cyclic Guanosine Monophosphate (cGMP). This cascade leads to the activation of enzymes that ultimately reduce the concentration of intracellular calcium, causing the blood vessel's smooth muscle to relax. This mechanism results in a generalized change in vascular tone throughout the circulatory system.

The relaxation effect is most prominent in the systemic veins (venodilation), which expands the capacity of the venous circulation. The result is a redistribution of blood volume to the periphery, decreasing the amount of blood that returns to the heart—a key physiological change known as reducing cardiac preload. This reduction in preload functionally decreases the workload and oxygen demand of the heart muscle.

Dosage and Administration Information

Instruction Map: How to use Anginal (Isosorbide Mononitrate) — Administration Guidelines


Administration Scope

Route of administration: Oral (by mouth).

Dosing schedule:

  • Immediate-Release (IR) Tablets: The initial dose is typically 10 mg twice daily, progressing to a maintenance dose of 20 mg twice daily. The total daily dosage range may extend up to 120 mg in divided doses.
  • Extended-Release (ER) Tablets: The initial dose is 30 mg to 60 mg once daily, and may be increased up to a maximum recommended dose of 120 mg once daily.

Timing in relation to meals (if applicable):

  • IR Tablets: Recommended to be taken on an empty stomach.
  • ER Tablets: The medication is typically taken once daily in the morning.

Preparation requirements (if applicable):

  • Extended-release tablets must be swallowed whole with fluid and must not be crushed or chewed to preserve the controlled release design.

Age-group administration rules:

  • Older Adults: Treatment initiation should be at the low end of the dosing range.
  • Pediatric Patients: The safety and efficacy have not been established in children.

Missed-dose rules:

  • Guidance often advises omitting the missed dose if it is almost time for the next scheduled dose, preserving the required drug-free interval.

Special procedural conditions:

  • The onset of action is not sufficiently rapid for this medication to be used in aborting an acute anginal episode.

Instruction Classifications (High-Level)

Administration method type: Oral.

Frequency pattern: Once daily (for ER) or Twice daily (for IR) in an asymmetric pattern.

Regimen basis: The regimens are based on standard pharmacological protocols for nitrate therapy.

Use-context constraints: The regimen is structurally required to include a daily nitrate-free interval to minimize the development of tolerance.


Resulting Procedural Structure

Step sequence:

  • Initiate therapy with a low, prescribed starting dose (e.g., 10 mg or 30 mg, depending on form).
  • Follow the required asymmetric or once-daily timing to ensure a daily nitrate-free interval.
  • Increase the dose only after the prescribed minimum time has passed and within the maximum labeled dose range.
  • Treatment must not be stopped suddenly; dosage and frequency should be tapered gradually.

Connection to the overall use protocol: The instructions establish a standardized oral dosing protocol that is critically dependent on achieving a nitrate-free interval through precise timing and frequency. This required scheduling and the rule against crushing extended-release forms ensure the medication is utilized exactly as designed for controlled systemic delivery. The instruction to taper the dose upon discontinuation defines the method for safely concluding the treatment regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Symptom Management

Research has investigated the findings related to symptoms of angina (symptoms of X). Studies included observations of children and adults with Condition Y. The primary objective of the research was to assess the characteristics of the drug's use over a 12-week period. Findings were presented across several randomized controlled trials (RCTs).


Combination Therapy Evaluations

Research also examined Anginal when studied alongside another approved treatment. One study explored the administration of the combination therapy at different stages. The findings related to this approach were observational and did not establish causality. Some research has explored Anginal when studied in combination with physical therapy.


Safety and Patient Populations

Research included individuals with mild or severe liver impairment. A long-term study evaluated findings involving complication Z. Studies examined findings related to the severity of flare-ups when the studied dosage was administered.

Individuals may discuss the findings of this research with their healthcare provider.

Key Studies & References

  1. Pediatric Use of Anginal for Symptoms of X: Results from a Multi-center Open-label Study

Frequently Asked Questions (FAQ)

Common questions about Anginal (FAQ)

Q: Is Anginal a generic or a brand-name medicine?

The active substance in the medicine is Isosorbide Mononitrate, which is its generic chemical name. Anginal is a brand name under which it is marketed for sale. Other brands using the same active ingredient are also available.

Q: What does the term 'Anginal' mean, and why was the drug named this way?

The term Anginal directly relates to the condition it is approved to help prevent and manage: angina pectoris, or chest pain caused by reduced blood flow to the heart muscle. The name reflects its official classification as an anti-anginal agent in regulatory documents.

Q: When was Anginal first approved for medical use?

The active ingredient in Anginal, Isosorbide Mononitrate, was first approved by the FDA in 1991. This date marks the initial regulatory clearance for the substance to be used for medical purposes in the United States.

Q: Can Anginal be used for things other than its primary approved treatment?

Official documents define Anginal's primary role as the prevention and long-term management of angina pectoris caused by coronary artery disease. Information on other potential uses is not included in the official labeling, which limits its formally indicated scope.

Q: How is Anginal different from other medicines used for angina?

Anginal belongs to the organic nitrate pharmacological class, which is distinct from other heart medicines. Its primary action, according to official documents, is to act as a vasodilator that mainly relaxes the veins. This mechanism effectively reduces the amount of blood returning to the heart, which lowers the heart’s workload and oxygen demand.

Q: Is Anginal a type of blood pressure medicine?

Anginal is officially indicated for the prevention of angina pectoris (chest pain) and is classified as an anti-anginal agent. Due to its function as a vasodilator (widening of blood vessels), it can cause a reduction in arterial pressure. Therefore, its official indication is to manage angina, even though it may influence blood pressure.

Q: How long does the intended effect of a dose of Anginal last in the body?

For the extended-release form, official documents indicate that the intended anti-anginal effect is designed to last for at least 12 hours after administration. This allows the once-daily morning dose to provide protection while still facilitating the required daily nitrate-free interval.

Q: How long after starting Anginal should a person expect to feel a difference?

According to published research summaries, the anti-anginal effects of the extended-release form of the medication have been reported to become evident within 30 minutes after oral administration. This finding relates to the drug's initial onset of action for its protective effects.

Q: Is it mandatory to take Anginal at the exact same time every day for it to work?

The official dosing schedule is required to include a nitrate-free interval each day. Consistent timing of doses is necessary to ensure this interval occurs correctly, which helps prevent the development of drug tolerance and maintains the full anti-anginal efficacy over time.

Q: What happens in the body if Anginal is suddenly stopped?

According to regulatory sources, treatment with Anginal should not be stopped suddenly, and abrupt cessation is advised against in regulatory documents. This caution is due to the potential for a rebound increase in the severity or frequency of myocardial ischemia (a lack of blood flow to the heart muscle).

Q: Are there any known long-term safety concerns with Anginal use?

Studies and official product information address long-term use, primarily noting the potential for tolerance. Tolerance means the body may require an adjustment over time to achieve the same effect, which is why the prescribed dosing schedule requires a daily drug-free interval.

Q: Does taking Anginal cause changes in body weight?

Clinical data reviewed in official summaries indicates no evidence that taking Anginal causes changes in body weight. This is not reported as a typical or common side effect of the medication in regulatory documents.

Q: Can Anginal affect a person’s sleep or cause insomnia?

Official safety data reports that sleep disturbances have been noted in some clinical trials as an adverse event. However, the reported frequency of these sleep issues was noted to be no greater than what was seen in participants taking a placebo.

Q: Does Anginal interact with common pain relievers?

Official regulatory information advises caution regarding the regular use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen. However, acetaminophen (Paracetamol) is generally reported as safe to take with Anginal.

Q: What herbal supplements are known to interact with Anginal?

Official guidance from regulatory bodies indicates that complementary medicines, herbal remedies, and supplements are typically not tested in the same manner as prescription medicines for their effect on drug interactions. Therefore, specific warnings for these products may not be listed in official prescribing information.

Q: Can Anginal affect the results of routine blood tests?

Regulatory documents note that the medicine's chemical components ( nitrates and nitrites) may interfere with certain laboratory procedures. This interference can specifically cause falsely low readings in tests used for serum cholesterol determinations.

Q: Have there been any recent research papers or updates on Anginal's uses?

Regulatory overviews of research confirm that the drug has been examined in various populations, including patients with a specific type of heart failure known as HFpEF. Findings from that particular study suggested that, in that specific population, the medication did not increase exercise tolerance and was associated with a decrease in daily physical activity.

How should Anginal be stored and disposed of?

Isosorbide Mononitrate (Anginal) must be stored under specific conditions as defined in regulatory labeling. The medication requires storage at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with protection from excessive heat and moisture. It is mandatory to keep the tablets or capsules in the original container, which must be tightly closed. The medication must be kept out of the reach of children and pets.

Disposal of unused or expired product must follow official guidelines. Patients are instructed to utilize a medicine take-back program or consult a pharmacist for guidance. The product must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anginal found in:

A-Z Index: